Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecapegfilgrastim Timing for Stem Cell Mobilization in MM and Lymphoma
NCT05294055Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2022
- Primary completion
- Mar 2026
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of mecapegfilgrastim in multiple myeloma (MM), lymphoma, sponsored by Institute of Hematology and Blood Diseases Hospital. Started Apr 2022; status: recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
multiple myeloma (MM)lymphoma
Beyond the preview
Go deeper on NCT05294055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05294055.